An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients

References

• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.
   PubMed Web of Science ®Google Scholar
• Collaborators GCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Betriu A, Martinez-Alonso M, Arcidiacono MV, et al. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol Dial Transplant. 2014 Jul;29(7):1415–1422.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514–525.
   PubMed Web of Science ®Google Scholar
• Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015 Jul;30(7):1162–1169.
   PubMed Web of Science ®Google Scholar
• Valdivielso JM, Betriu A, Martinez-Alonso M, et al. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS One. 2017;12(10):e0186665.
   PubMed Web of Science ®Google Scholar
• Arroyo D, Betriu A, Martinez-Alonso M, et al. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014;15:168.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Li S, Jurkovitz CT, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug;156(2):277–283.
   PubMed Web of Science ®Google Scholar
• Gracia M, Betriu À, Martínez-Alonso M, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. 2016 Feb;11(2):287–296.
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Žutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Carrero JJ, Nordfors L, et al. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol. 2008 Sep-Oct;21(5):635–644.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017 Apr;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Navab KD, Elboudwarej O, Gharif M, et al. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des. 2011;17(1):17–20.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014 May;(5):CD007784.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul;353(3):238–248.
   PubMed Web of Science ®Google Scholar
• Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr;360(14):1395–1407.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun;377(9784):2181–2192.
   PubMed Web of Science ®Google Scholar
• Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006 Nov;116(11):2995–3005.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006 Mar;354(12):1264–1272.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016 06;57(6):1086–1096.
   PubMed Web of Science ®Google Scholar
• Elewa U, Fernández-Fernández B, Mahillo-Fernández I, et al. PCSK9 in diabetic kidney disease. Eur J Clin Invest. 2016 Sep;46(9):779–786.
   PubMed Web of Science ®Google Scholar
• Konarzewski M, Szolkiewicz M, Sucajtys-Szulc E, et al. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol. 2014;40(2):157–163.
   PubMed Web of Science ®Google Scholar
• Abujrad H, Mayne J, Ruzicka M, et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 2014 Mar;233(1):123–129.
   PubMed Web of Science ®Google Scholar
• Ramasamy I. Update on the laboratory investigation of dyslipidemias. Clin Chim Acta. 2018 Jan;479:103–125.
   PubMed Web of Science ®Google Scholar
• Amor AJ, Catalan M, Pérez A, et al. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis. 2016;247:161–169.
   PubMed Web of Science ®Google Scholar
• Holmes MV, Millwood IY, Kartsonaki C, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol. 2018 Feb;71(6):620–632.
   PubMed Web of Science ®Google Scholar
• Gluba-Brzózka A, Franczyk B, Banach M, et al. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol. 2017 Jan;49(1):155–164.
   PubMed Web of Science ®Google Scholar
• Gluba-Brzozka A, Franczyk B, Bartnicki P, et al. Lipoprotein subfractions, uric acid and cardiovascular risk in End-Stage Renal Disease (ESRD) patients. Curr Vasc Pharmacol. 2017;15(2):123–134.
   PubMed Web of Science ®Google Scholar
• Rysz-Gorzynska M, Gluba-Brzozka A, Banach M. High-density lipoprotein and low-density lipoprotein subfractions in patients with chronic kidney disease. Curr Vasc Pharmacol. 2017;15(2):144–151.
   PubMed Web of Science ®Google Scholar
• Alabakovska SB, Todorova BB, Labudovic DD, et al. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002 May;35(3):211–216.
   PubMed Web of Science ®Google Scholar
• Homma K, Homma Y, Shiina Y, et al. Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment. Nephron Clin Pract. 2013;123(1–2):41–45.
   PubMedGoogle Scholar
• Honda H, Hirano T, Ueda M, et al. High-density lipoprotein subfractions and their oxidized subfraction particles in patients with chronic kidney disease. J Atheroscler Thromb. 2016;23(1):81–94.
   PubMed Web of Science ®Google Scholar
• Noori N, Caulfield MP, Salameh WA, et al. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2011 Dec;6(12):2861–2870.
   PubMed Web of Science ®Google Scholar
• Savic J, Zeljkovic A, Bogavac-Stanojevic N, et al. Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease. Scand J Clin Lab Invest. 2014 Oct;74(7):637–643.
   PubMed Web of Science ®Google Scholar
• Shen H, Xu Y, Lu J, et al. Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol. 2016 Oct;17(1):143.
   PubMed Web of Science ®Google Scholar
• Kanda E, Ai M, Okazaki M, et al. Association of high-density lipoprotein subclasses with chronic kidney disease progression, atherosclerosis, and klotho. PLoS One. 2016;11(11):e0166459.
   PubMed Web of Science ®Google Scholar
• Mallol R, Amigó N, Rodríguez MA, et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res. 2015 Mar;56(3):737–746.
   PubMed Web of Science ®Google Scholar
• Junyent M, Martínez M, Borràs M, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol. 2010;11:14.
   PubMed Web of Science ®Google Scholar
• Junyent M, Martínez M, Borrás M, et al. Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrologia. 2010;30(1):119–126.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. NMR measurement of LDL particle number using the Vantera clinical analyzer. Clin Biochem. 2014 Nov;47(16–17):203–210.
   PubMed Web of Science ®Google Scholar
• Breiman L. Random forests. Mach Learn. 2001 October 01;45(1):5–32.
   Web of Science ®Google Scholar
• Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006 Sep 01;15(3):651–674.
   Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837–845.
   PubMed Web of Science ®Google Scholar
• Bermúdez-López M, Betriu À, Valdivielso JM, et al. Beyond the traditional lipid parameters in chronic kidney disease. Nefrologia. 2017 Nov;38(2):109-113.
   PubMedGoogle Scholar
• Kwan BC, Kronenberg F, Beddhu S, et al. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007 Apr;18(4):1246–1261.
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016 07;57(7):1111–1125.
   PubMed Web of Science ®Google Scholar
• Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis. 2016;15:95.
   PubMed Web of Science ®Google Scholar
• Kollerits B, Drechsler C, Krane V, et al. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D study. Nephrol Dial Transplant. 2016 Nov;31(11):1901–1908.
   PubMed Web of Science ®Google Scholar
• Konishi H, Miyauchi K, Tsuboi S, et al. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol. 2016;205:50–53.
   PubMed Web of Science ®Google Scholar
• Lin J, Khetarpal SA, Terembula K, et al. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol. 2015;16:130.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Zaritsky JJ, Fornoni A, et al. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018 Jan;14(1):57–70.
   PubMed Web of Science ®Google Scholar
• Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant. 2014 Mar;29(3):538–543.
   PubMed Web of Science ®Google Scholar
• Haas ME, Levenson AE, Sun X, et al. The role of proprotein convertase Subtilisin/Kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation. 2016 Jul;134(1):61–72.
   PubMed Web of Science ®Google Scholar
• Jin K, Park BS, Kim YW, et al. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014 Apr;63(4):584–589.
   PubMed Web of Science ®Google Scholar
• Morena M, Le May C, Chenine L, et al. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol. 2017 Jan-Feb;11(1):87–93.
   PubMed Web of Science ®Google Scholar
• Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010 Jun;51(6):1486–1495.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2185–2191.
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013 Sep;128(11):1189–1197.
   PubMed Web of Science ®Google Scholar
• Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 May;192(1):211–217.
   PubMed Web of Science ®Google Scholar
• Bermúdez-López M, Arroyo D, À B, et al. New perspectives on CKD-induced dyslipidemia. Expert Opin Ther Targets. 2017 Oct;21(10):967–976.
   PubMed Web of Science ®Google Scholar
• Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171–183.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014 Mar;141(3):358–367.
   PubMed Web of Science ®Google Scholar
• Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992 Apr;93(3):189–199.
   PubMed Web of Science ®Google Scholar
• Bowden RG, Wilson RL, Beaujean AA. LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients. J Nephrol. 2011 Nov-Dec;24(6): 771–777.
   PubMed Web of Science ®Google Scholar
• Shrestha P, van de Sluis B, Dullaart RPF, et al. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal. 2019;55:53–64.
   PubMed Web of Science ®Google Scholar